
Novocure (NVCR) Stock Forecast & Price Target
Novocure (NVCR) Analyst Ratings
Bulls say
NovoCure Ltd is poised for significant revenue growth due to a recent study that could enable Glioblastoma (GBM) patients to start treatment 2-3 months earlier, potentially increasing revenue per patient by 20-30%. The company is also expected to see a rise in active patients driven by growth in the U.S. and Germany, which serve as key markets and are indicative of future revenue trajectories. Additionally, the introduction of new markets within the next 12-18 months is anticipated to further enhance revenue streams, supplementing existing growth drivers.
Bears say
The financial outlook for NovoCure indicates a significant decline in EBITDA as revenue is expected to ramp up gradually over the upcoming quarters. Analysts estimate that the company may only reach breakeven levels in EBITDA by 2027, suggesting a prolonged period of financial strain. This projected timeline for achieving profitability raises concerns about the sustainability of the company's operations amid ongoing investments in its pipeline and product development.
This aggregate rating is based on analysts' research of Novocure and is not a guaranteed prediction by Public.com or investment advice.
Novocure (NVCR) Analyst Forecast & Price Prediction
Start investing in Novocure (NVCR)
Order type
Buy in
Order amount
Est. shares
0 shares